Jazz Pharmaceuticals PLC (JAZZ) Stock Forecast & Price Target
Jazz Pharmaceuticals PLC · NASDAQ
$240.06-6.75 (-2.73%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 16 firms covering Jazz Pharmaceuticals PLC, 15 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $225.00 to $322.00, a moderate spread. The average target of $285.31 sits 19% above the current $240.06. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $6.45 next quarter toward $25.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 ratings
Strong Buy
Strong Buy00%
Buy1594%
Hold16%
Sell00%
Strong Sell00%
Based on 16 analysts giving stock ratings to Jazz Pharmaceuticals PLC.
As of Sep, 15 of 16 firms rate JAZZ a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
JAZZ EPS & revenue forecast
EPS · NEXT QUARTER
$6.45
Range $5.78 – $8.17 · 16 analysts · -3% YoY
Next period, 16 analysts expect Jazz Pharmaceuticals PLC to earn $6.45 a share (range $5.78 – $8.17), versus $6.64 a year earlier. Full-year consensus is $25.03, growing to $25.77 the year after.
REVENUE · NEXT QUARTER
$1.2B
Range $1.2B – $1.3B · 16 analysts · +3% YoY
Revenue is expected to reach $1.2B (range $1.2B – $1.3B), +2.8% year-over-year. Full-year consensus is $4.7B, rising to $5.0B next year.
Top analysts covering Jazz Pharmaceuticals PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JAZZ.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Buy
$322.00+34.1% to target
Overall win rate
64%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #33
Buy
$299.00+24.6% to target
Overall win rate
48%
+ Follow
#3
Ami Fadia
Needham · Rank #67
Buy
$310.00+29.1% to target
Overall win rate
47%
+ Follow
#4
Jessica Fye
JP Morgan · Rank #71
Buy
$276.00+15.0% to target
Overall win rate
53%
+ Follow
#5
Joel Beatty
Baird · Rank #80
Buy
$280.00+16.6% to target
Overall win rate
48%
+ Follow
JAZZ stock forecast FAQ
What is JAZZ's average 12-month price target?+
The 16 analysts with a live target average $285.31 for Jazz Pharmaceuticals PLC over the next 12 months, ranging from a $322.00 high to a $225.00 low.
Is JAZZ stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 16 analyst ratings, 15 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for JAZZ?+
The Street-high target is $322.00 (Morgan Stanley), and the Street-low is $225.00 (Leerink Partners). The average of all 16 active targets is $285.31.
How many Wall Street analysts cover JAZZ?+
16 analysts have an active rating on Jazz Pharmaceuticals PLC, and 16 firms carry a live 12-month price target.
Who is the most accurate analyst covering JAZZ?+
Among analysts who currently cover JAZZ, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Buy with a $322.00 target.
What is Jazz Pharmaceuticals PLC's projected EPS for next quarter?+
The consensus estimate is $6.45 per share (range $5.78 – $8.17) across 16 analysts. Full-year EPS is projected at $25.03, rising to $25.77 the following year.
How much revenue is Jazz Pharmaceuticals PLC expected to report next quarter?+
Consensus revenue is $1.2B (range $1.2B – $1.3B). Full-year revenue is projected at $4.7B, growing to $5.0B next year.
Have analysts been upgrading or downgrading JAZZ lately?+
As of Sep, 15 of 16 firms rate JAZZ a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JAZZ calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Deutsche Bank
